Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.
Brian I. Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, spoke with CancerNetwork® at the 2021 European Society for Medical Oncology (ESMO) Congress about his expectations for the results of the upcoming randomized, open-label, phase 3 trial (NCT04736706). The 3-arm study will compare MK-1308A or belzutifan (Welireg) added to lenvatinib (Lenvima) and pembrolizumab (Keytruda) versus the control arm of pembrolizumab plus lenvatinib to treat advanced clear cell renal cell carcinoma in the first-line setting.
The trial’s powered for overall survival and we’ll also look at progression-free survival, response rate, and other typical end points. If positive, it would presumably set a new standard of care and ideally care [for] more patients. We’re now at the point in kidney cancer where we’re curing around 15% to 20% of patients, but that’s obviously still the minority of patients. The hope is, as has been done in other malignancies, by building combination regimens, we can care more patients. That's absolutely the goal.
Rini BI, Plimack ER, Powles TB, et al. Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol. 2021;32(suppl 5):717TiP. doi:10.1016/annonc/annonc675
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.